|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: AKAP7 |
Gene summary for AKAP7 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | AKAP7 | Gene ID | 9465 |
| Gene name | A-kinase anchoring protein 7 | |
| Gene Alias | AKAP15 | |
| Cytomap | 6q23.2 | |
| Gene Type | protein-coding | GO ID | GO:0007154 | UniProtAcc | O43687 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9465 | AKAP7 | S43 | Human | Liver | Cirrhotic | 2.86e-11 | -4.46e-01 | -0.0187 |
| 9465 | AKAP7 | HCC1_Meng | Human | Liver | HCC | 1.01e-16 | -5.87e-01 | 0.0246 |
| 9465 | AKAP7 | HCC2_Meng | Human | Liver | HCC | 7.14e-13 | -5.70e-01 | 0.0107 |
| 9465 | AKAP7 | cirrhotic1 | Human | Liver | Cirrhotic | 6.78e-03 | -2.78e-01 | 0.0202 |
| 9465 | AKAP7 | cirrhotic2 | Human | Liver | Cirrhotic | 8.51e-20 | 1.85e-01 | 0.0201 |
| 9465 | AKAP7 | cirrhotic3 | Human | Liver | Cirrhotic | 5.17e-07 | -2.16e-01 | 0.0215 |
| 9465 | AKAP7 | HCC2 | Human | Liver | HCC | 2.82e-06 | 1.61e+00 | 0.5341 |
| 9465 | AKAP7 | HCC5 | Human | Liver | HCC | 2.97e-12 | 1.16e-01 | 0.4932 |
| 9465 | AKAP7 | Pt13.a | Human | Liver | HCC | 1.16e-10 | -5.50e-01 | 0.021 |
| 9465 | AKAP7 | Pt13.b | Human | Liver | HCC | 1.37e-11 | -5.46e-01 | 0.0251 |
| 9465 | AKAP7 | Pt13.c | Human | Liver | HCC | 5.11e-13 | -6.06e-01 | 0.0076 |
| 9465 | AKAP7 | Pt14.c | Human | Liver | HCC | 3.40e-02 | -5.53e-01 | 0.0054 |
| 9465 | AKAP7 | Pt14.d | Human | Liver | HCC | 1.62e-03 | -4.61e-01 | 0.0143 |
| 9465 | AKAP7 | S014 | Human | Liver | HCC | 1.45e-02 | -3.03e-01 | 0.2254 |
| 9465 | AKAP7 | S016 | Human | Liver | HCC | 3.43e-08 | -4.83e-01 | 0.2243 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| AKAP7 | SNV | Missense_Mutation | novel | c.952N>A | p.Glu318Lys | p.E318K | Q9P0M2 | protein_coding | deleterious(0.03) | probably_damaging(0.998) | TCGA-A2-A25C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD |
| AKAP7 | insertion | Frame_Shift_Ins | novel | c.849_850insACGTCTGTAATCCCAGCACTTTGGGA | p.Gly284ThrfsTer22 | p.G284Tfs*22 | Q9P0M2 | protein_coding | TCGA-A8-A09A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| AKAP7 | SNV | Missense_Mutation | novel | c.787T>G | p.Cys263Gly | p.C263G | Q9P0M2 | protein_coding | deleterious(0.02) | probably_damaging(0.997) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| AKAP7 | SNV | Missense_Mutation | c.868G>C | p.Glu290Gln | p.E290Q | Q9P0M2 | protein_coding | deleterious(0.04) | possibly_damaging(0.468) | TCGA-EK-A2RN-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| AKAP7 | SNV | Missense_Mutation | c.192N>C | p.Glu64Asp | p.E64D | Q9P0M2 | protein_coding | tolerated(0.05) | benign(0.007) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| AKAP7 | SNV | Missense_Mutation | c.130N>C | p.Asp44His | p.D44H | Q9P0M2 | protein_coding | deleterious(0) | possibly_damaging(0.831) | TCGA-IR-A3LL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| AKAP7 | deletion | Frame_Shift_Del | rs764761178 | c.229delN | p.Lys79ArgfsTer21 | p.K79Rfs*21 | Q9P0M2 | protein_coding | TCGA-VS-A94Z-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | ||
| AKAP7 | SNV | Missense_Mutation | c.847N>G | p.Ile283Val | p.I283V | Q9P0M2 | protein_coding | tolerated(0.53) | benign(0.007) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| AKAP7 | SNV | Missense_Mutation | novel | c.56N>T | p.Arg19Ile | p.R19I | Q9P0M2 | protein_coding | deleterious(0.01) | benign(0.219) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| AKAP7 | SNV | Missense_Mutation | novel | c.641N>T | p.Arg214Ile | p.R214I | Q9P0M2 | protein_coding | deleterious(0) | possibly_damaging(0.664) | TCGA-AG-3892-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |